Zomedica Statistics
Total Valuation
Zomedica has a market cap or net worth of 39.30 million. The enterprise value is -16.25 million.
| Market Cap | 39.30M |
| Enterprise Value | -16.25M |
Important Dates
The last earnings date was Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zomedica has 979.95 million shares outstanding.
| Current Share Class | 979.95M |
| Shares Outstanding | 979.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.79% |
| Owned by Institutions (%) | 0.57% |
| Float | 951.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.39 |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.19 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.69 |
Financial Position
The company has a current ratio of 8.44, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.44 |
| Quick Ratio | 7.50 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.11 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.95% and return on invested capital (ROIC) is -11.93%.
| Return on Equity (ROE) | -50.95% |
| Return on Assets (ROA) | -11.35% |
| Return on Invested Capital (ROIC) | -11.93% |
| Return on Capital Employed (ROCE) | -25.21% |
| Revenue Per Employee | 186,553 |
| Profits Per Employee | -559,855 |
| Employee Count | 152 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 1.55 |
Taxes
| Income Tax | -293,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.24% in the last 52 weeks. The beta is 1.61, so Zomedica's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -74.24% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 51.35 |
| Average Volume (20 Days) | 1,122,260 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.28 |
Income Statement
In the last 12 months, Zomedica had revenue of 28.36 million and -85.10 million in losses. Loss per share was -0.09.
| Revenue | 28.36M |
| Gross Profit | 19.68M |
| Operating Income | -32.35M |
| Pretax Income | -85.39M |
| Net Income | -85.10M |
| EBITDA | -24.14M |
| EBIT | -32.35M |
| Loss Per Share | -0.09 |
Balance Sheet
The company has 58.07 million in cash and 2.52 million in debt, giving a net cash position of 55.55 million or 0.06 per share.
| Cash & Cash Equivalents | 58.07M |
| Total Debt | 2.52M |
| Net Cash | 55.55M |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | 125.36M |
| Book Value Per Share | 0.13 |
| Working Capital | 60.48M |
Cash Flow
In the last 12 months, operating cash flow was -21.41 million and capital expenditures -2.07 million, giving a free cash flow of -23.48 million.
| Operating Cash Flow | -21.41M |
| Capital Expenditures | -2.07M |
| Free Cash Flow | -23.48M |
| FCF Per Share | -0.02 |
Margins
| Gross Margin | 69.41% |
| Operating Margin | -114.09% |
| Pretax Margin | -301.14% |
| Profit Margin | n/a |
| EBITDA Margin | -85.12% |
| EBIT Margin | -114.09% |
| FCF Margin | n/a |
Dividends & Yields
Zomedica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -216.56% |
| FCF Yield | -59.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zomedica has an Altman Z-Score of 2.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.51 |
| Piotroski F-Score | 3 |